Next 10 |
home / stock / envb / envb articles
Enveric Biosciences (NASDAQ:ENVB) reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. "We believe the fi...
Psychedelics biotech firm, Enveric Biosciences (NASDAQ:ENVB) has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodru...
Enveric Biosciences (NASDAQ:ENVB), a Nasdaq-listed psychedelics biotech firm, has entered into a non-binding term sheet with an undisclosed biotech...
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS...
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Do...
Enveric Biosciences (NASDAQ:ENVB) shares are trading higher after the company signed two non-binding term sheets with an undisclosed biotechno...
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.3% on Thursday. The Dow traded down 0.08% to 38,919.26 wh...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter fin...
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded down 0.16% to 38,8...
News, Short Squeeze, Breakout and More Instantly...
Enveric Biosciences Inc Com Company Name:
ENVB Stock Symbol:
NASDAQ Market:
Enveric Biosciences Inc Com Website:
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 ...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Com...